Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
about
Advances in sarcoma diagnostics and treatmentCurrent classification, treatment options, and new perspectives in the management of adipocytic sarcomasRecent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapyEfficacy and safety of eribulin mesylate in advanced soft tissue sarcomasA Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor ActivitySystemic treatment in advanced soft tissue sarcoma: what is standard, what is new.Breast Cancer Cell Lines Exhibit Differential Sensitivities to Microtubule-targeting Drugs Independent of Doubling Time.In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumabClinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.Design, synthesis, and structure-activity relationships of pyrimido[4,5-b]indole-4-amines as microtubule depolymerizing agents that are effective against multidrug resistant cells.Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?Microtubule destabilising agents: far more than just antimitotic anticancer drugs.Eribulin shows high concentration and long retention in xenograft tumor tissues.Identification of 7-(4'-Cyanophenyl)indoline-1-benzenesulfonamide as a mitotic inhibitor to induce apoptotic cell death and inhibit autophagy in human colorectal cancer cellsMarine Sponge Natural Products with Anticancer Potential: An Updated Review.Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies.Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer.Eribulin in advanced breast cancer: safety, efficacy and new perspectives.Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.Advances in the treatment of soft tissue sarcoma: focus on eribulin.Regulation of E-cadherin localization by microtubule targeting agents: rapid promotion of cortical E-cadherin through p130Cas/Src inhibition by eribulin.Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma.miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer.
P2860
Q28069695-C98ECE15-DBBC-4C52-A24B-0595698FFD25Q28076210-8C16DDD0-42B9-4A83-B04C-9CF0ECE4029CQ28076992-192C3913-1D1E-482C-80FD-72B75A1741C6Q28078116-CAAC8BA7-ADB3-4A3D-821A-9FE1091BB396Q28830651-E6A4EFDD-A936-4A1A-84C1-9CCCA1B53898Q36389964-DF32F1F2-180A-4EAD-B1DA-AF53AD2C316FQ36742357-EB365F40-7CC6-4E50-B203-4086DF25CC0AQ36964337-8D3F1E49-2081-4D97-BB0F-67DDDAB698BAQ38688042-151DC7B0-2995-48FC-8067-DF0A34088CEFQ38700436-3172E34D-C555-455F-93ED-6D6573BE5447Q38769613-4EA4598C-4B0B-4848-BB42-9A3AEC7C94A2Q38952778-1D6844EB-3F64-4D45-8953-0519149AAD19Q41159925-C69F9809-2635-423F-9B95-DD89D89E919AQ42132814-4B6D00A8-AC11-4A9A-A555-CE17AFA2A569Q43245354-36CE9E6A-7F15-4E20-BA58-A82AEAAFA461Q45392298-0B64C593-5407-4443-BF60-3282BCE77084Q46592179-C463E969-1609-4B40-AC0B-45D667D45206Q47794057-6B824760-21F7-4725-A9F1-CE19AC1E2F62Q48305630-BFEF2559-6876-438F-9E44-A4DC2AC7A1B6Q49261685-50698068-79CB-46FD-966E-82C4056C0DD3Q49787954-064F5792-7B5E-486D-88C2-2B425DB35B07Q50456986-61C4215D-6ACA-44CC-866D-6F70BAB1F3FDQ53695419-CBF05016-D210-4B0B-A431-B3B2BE607A07
P2860
Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
@ast
Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
@en
type
label
Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
@ast
Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
@en
prefLabel
Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
@ast
Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
@en
P2860
P1476
Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
@en
P2093
April L Risinger
Susan L Mooberry
P2860
P304
P356
10.1158/1078-0432.CCR-14-3252
P407
P577
2015-04-02T00:00:00Z